erytromycine

J - Antiinfectives For Systemic Use -> J01 - Antibacterials For Systemic Use -> J01F - Macrolides, Lincosamides And Streptogramins -> J01FA - Macrolides -> J01FA01 - Erythromycin
Administration category: Free Medicine group: antibacterial

Safety margins

≥ 18 years
WeightROADosage
ROA:
po
Dosage:
min. 250mg 4 dd to max. 1000mg 4 dd
ROA:
iv
Dosage:
min. 250mg 4 dd to max. 1000mg 4 dd

Kidney function

Renal elimination: 2-15%
Dosage: independent on kidney function

Interactions

Interaction with (ATC): Expected effect:
Interaction with (ATC):
N03AF01 - Carbamazepine
Expected effect:
verhoging plasmaconcentratie carbamazepine
Interaction with (ATC):
L04AD01 - Ciclosporin
Expected effect:
verhoging concentratie ciclosporine
Interaction with (ATC):
L04AD02 - Tacrolimus
Expected effect:
verhoging concentratie tacrolimus
Interaction with (ATC):
L04AA10 - Sirolimus
Expected effect:
verhoging concentratie sirolimus
Interaction with (ATC):
R06AX12 - Terfenadine
Expected effect:
toename cardiotoxiciteit
Interaction with (ATC):
A03FA02 - Cisapride
Expected effect:
toename cardiotoxiciteit
Interaction with (ATC):
C01BA03 - Disopyramide
Expected effect:
toename cardiotoxiciteit
Interaction with (ATC):
C01AA05 - Digoxin
Expected effect:
verhoging plasmaconcentratie digoxine
Interaction with (ATC):
R03DA04 - Theophylline
Expected effect:
verhoging plasmaconcentratie theofylline
Interaction with (ATC):
J05AE - Protease Inhibitors
Expected effect:
verhoging plasmaconcentratie erytromycine

Pregnancy

Due to the expiration of the alphanumeric classification for use in pregnancy and lactation, reference is made to the current, online information of the Teratology Information Service (TIS) of LAREB:

For individual advice, consult an expert on site.
Metadata

Swab vid: M-1388.1
Updated: 06/16/2019 - 20:05
Status: Published

External links
Menu position